Clinical Trial Results: First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) [Phase 1, Phase 2]

View source ↗

Summary

First-in-human study results for SAR443579 in relapsed or refractory acute leukemias and BPDCN across Phase 1/2 cohorts; the study was terminated with posted re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Blastic Plasmacytoid Dendritic Cell Neoplasm
• Lymphocytic Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• SAR443579

Snippet

Sponsor: Sanofi | Conditions: Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-07-06